Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 7/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7343114 | 1.00 | CHRM2 (0.39) | CHRM2CHRM1CHRM4CHRM3CHRM5 | |
| SCHEMBL1412253 | 1.00 | CHRM2 (0.39) | CHRM2CHRM1CHRM4CHRM3CHRM5 | |
| SCHEMBL18605578 | 1.00 | CHRM2 (0.39) | CHRM2CHRM1CHRM4CHRM3CHRM5 | |
| SCHEMBL6060648 | 0.88 | CHRM2 (0.35) | CHRM2CHRM1CHRM4CHRM3CHRM5 | |
| SCHEMBL2327031 | 0.87 | CHRM2 (0.43) | CHRM2CHRM1CHRM4CHRM3CHRM5 | |
| SCHEMBL5176012 | 0.87 | CHRM2 (0.43) | CHRM2CHRM1CHRM4CHRM3CHRM5 | |
| SCHEMBL2327034 | 0.87 | CHRM2 (0.43) | CHRM2CHRM1CHRM4CHRM3CHRM5 | |
| SCHEMBL2329374 | 0.87 | CHRM2 (0.43) | CHRM2CHRM1CHRM4CHRM3CHRM5 | |
| SCHEMBL5175556 | 0.87 | CHRM2 (0.43) | CHRM2CHRM1CHRM4CHRM3CHRM5 | |
| SCHEMBL2327041 | 0.87 | CHRM2 (0.43) | CHRM2CHRM1CHRM4CHRM3CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023009585-A2 | TRANSTHYRETIN STABILIZING COMPOUNDS | PROTEGO BIOPHARMA, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| EP-2044070-B1 | PURINE DERIVATIVES AS A2A AGONISTS | NOVARTIS AG (CH) | 2012-08-22 | — | — | EP | disclosed |
| US-8071565-B2 | Purine derivatives as a2a agonists | NOVARTIS AG (CH) | 2011-12-06 | — | — | US | disclosed |
| US-20100240680-A1 | Purine derivatives as a2a agonists | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| EP-1889846-A1 | Purine derivatives as A2a agonists | Novartis AG (CH) | 2008-02-20 | — | — | EP | disclosed |
| US-6436947-B1 | TO PREVENT ALLOGRAFT REJECTION; AUTOIMMUNE DISEASES DUE TO ACTION OF T-CELLS AS INSULIN-DEPENDENT DIABETES, MULTIPLE SCLEROSIS, RHEUMATOID ARTHRITIS; SUPPRESSION OF HUMORAL IMMUNE RESPONSE IN TREATMENT OF MYESTHENIAGRAVIS, LUPUS ERYTHEMATOSUS | AVENTIS PHARMACEUTICALS INC. | 2002-08-20 | — | — | US | disclosed |
| EP-0545413-B1 | Trans cyclopentanyl purine analogs useful as immunosuppressants | AVENTIS PHARMA INC (US) | 2000-07-12 | — | — | EP | disclosed |
| US-5929079-A | TREATMENT OF MYESTHENIAGRAVIS, MULTIPLE SCLEROSIS, SYSTEMIC LUPUS ERYTHEMATOSUS | HOECHST MARION ROUSSEL, INC. (US) | 1999-07-27 | — | — | US | disclosed |
| US-5916892-A | ADMINISTERING TO THE PATIENT SUFFERING OF ALLOGRAFT REJECTION, AUTOIMMUNE DISEASE, INSULIN-DEPENDENT DIABETIC MELLITUS, MULTIPLE SCLEROSIS, RHEUMATOID ARTHRITIS, MYESTHENIA GRAVIS, LUPUS ERYTHEMATOSUS AND SEPTIC SHOCK SYNDROME | HOECHST MARION ROUSSEL, INC. (US) | 1999-06-29 | — | — | US | disclosed |
| US-5905085-A | ANTIGENS AND IMMUNOSUPPRESSANTS | HOECHST MARION ROUSSEL, INC. (US) | 1999-05-18 | — | — | US | disclosed |
| US-5817660-A | TRIAZOLOPYRIMIDINES | HOECHST MARION ROUSSEL, INC. (US) | 1998-10-06 | — | — | US | disclosed |
| US-5817672-A | IMIDAZOPYRIDINES | HOECHST MARION ROUSSEL, INC. (US) | 1998-10-06 | — | — | US | disclosed |
| US-5817661-A | Trans cyclopentanyl purine analogs useful as immunosuppressants | HOECHST MARION ROUSSEL, INC. (US) | 1998-10-06 | — | — | US | disclosed |
| US-5808112-A | Preparation of cis-4-O-protected-2-cyclopentenol derivatives | HOECHST MARION ROUSSEL INC. (US) | 1998-09-15 | — | — | US | disclosed |
| US-5728899-A | Preparation of cis-4-O-protected-2-cyclopentenol derivatives | HOECHST MARION ROUSSEL INC. (US) | 1998-03-17 | — | — | US | disclosed |
| US-5723466-A | AUTOIMMUNE DISEASES, ANTIARTHRITIC AGENTS AND IMMUNOSUPPRESSANTS | HOECHST MARION ROUSSEL, INC. (US) | 1998-03-03 | — | — | US | disclosed |
| EP-0817764-A1 | PREPARATION OF CIS-4-O-PROTECTED-2-CYCLOPENTENOL DERIVATIVES | HOECHST MARION ROUSSEL, INC. (US) | 1998-01-14 | — | — | EP | disclosed |
| WO-1996031476-A1 | AROMATIC HYDROXYETHERS | RHONE-POULENC RORER LIMITED (GB) | 1996-10-10 | — | — | WO | disclosed |
| WO-1996030320-A1 | PREPARATION OF CIS-4-O-PROTECTED-2-CYCLOPENTENOL DERIVATIVES | HOECHST MARION ROUSSEL, INC. (US) | 1996-10-03 | — | — | WO | disclosed |
| EP-0545413-A1 | Novel trans cyclopentanyl purine analogs useful as immunosuppressants | HOECHST MARION ROUSSEL, INC. (US) | 1993-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240680-A1 | Purine derivatives as a2a agonists | ADORA2A, ADORA1, ADORA3 | CHRM2 39/4885CHRM1 26/4885CHRM4 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.